Document Detail

Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia.
Jump to Full Text
MedLine Citation:
PMID:  24812513     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Many studies have investigated the relationship between blood levels of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA-S), cortisol, progesterone, and testosterone and the onset, prognosis, symptom severity, and treatment response of schizophrenia. In the present study, we assessed potential differences in blood levels of neurosteroids between drug-naïve first-episode patients with schizophrenia (FES), and drug-free patients with schizophrenia who were not in the first episode but were in a phase of acute exacerbation (DFP).
MATERIALS AND METHODS: The present study included 32 male FES, 28 male DFP, and 24 male healthy controls (HC). Groups were compared in terms of blood levels of adrenocorticotropic hormone (ACTH), cortisol, testosterone, progesterone, and DHEA-S.
RESULTS: Blood levels of ACTH, cortisol, testosterone, and progesterone were similar among the groups. The mean value of serum DHEA-S was significantly different among the groups (P<0.001). The value of serum DHEA-S was higher in the FES group than in the DFP and HC groups (both P<0.001). The mean values of serum DHEA-S in the HC and DFP groups were found to be similar (P=0.33).
CONCLUSION: We suggest that higher values of DHEA-S in the FES group compared with both the DFP and HC groups indicate that this neurosteroid response is unique to first-episode schizophrenia patients. Further studies are needed to investigate the difference in blood levels of neurosteroids in different groups in terms of age of diagnosis.
Authors:
Murat Beyazyüz; Yakup Albayrak; Elmas Beyazyüz; Cüneyt Unsal; Erol Göka
Related Documents :
21725183 - Measurement of serum levels of mannose-binding lectin in hemodialysis patients: a compa...
21908203 - Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial struct...
1484713 - Plasma and cerebrospinal fluid beta-endorphin in chronic tension-type headache.
Publication Detail:
Type:  Journal Article     Date:  2014-04-29
Journal Detail:
Title:  Neuropsychiatric disease and treatment     Volume:  10     ISSN:  1176-6328     ISO Abbreviation:  Neuropsychiatr Dis Treat     Publication Date:  2014  
Date Detail:
Created Date:  2014-05-09     Completed Date:  2014-05-09     Revised Date:  2014-05-12    
Medline Journal Info:
Nlm Unique ID:  101240304     Medline TA:  Neuropsychiatr Dis Treat     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  687-93     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Neuropsychiatr Dis Treat
Journal ID (iso-abbrev): Neuropsychiatr Dis Treat
Journal ID (publisher-id): Neuropsychiatric Disease and Treatment
ISSN: 1176-6328
ISSN: 1178-2021
Publisher: Dove Medical Press
Article Information
Download PDF
© 2014 Beyazyüz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License
License:
collection publication date: Year: 2014
Electronic publication date: Day: 29 Month: 4 Year: 2014
Volume: 10First Page: 687 Last Page: 693
PubMed Id: 24812513
ID: 4011925
DOI: 10.2147/NDT.S61406
Publisher Id: ndt-10-687

Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia
Murat Beyazyüz1
Yakup Albayrak2
Elmas Beyazyüz3
Cüneyt Ünsal2
Erol Göka3
1Department of Psychiatry, Gölbaşı Hasvak State Hospital, Ankara, Turkey
2Department of Psychiatry, School of Medicine, Namık Kemal University, Tekirdağ, Turkey
3Department of Psychiatry, Ankara Numune Education and Research Hospital, Ankara, Turkey
Correspondence: Correspondence: Yakup Albayrak, Department of Psychiatry, School of Medicine, Namık Kemal University, Tunca Caddesi, Tekirdağ, 59100, Turkey, Tel +90 505 635 5434, Fax +90 282 250 9950, Email dr.fuge@hotmail.com

Introduction

Neuroactive steroids, such as cortisol, dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA-S), progesterone, and testosterone, are the steroid hormones that have several notable roles in the central nervous system.1,2 In the last 3 decades, several authors have posited a link between neuroactive steroids and the pathophysiology or therapeutics of schizophrenia. The relationship between blood levels of DHEA, DHEA-S, cortisol, progesterone, and testosterone and the onset, prognosis, symptom severity, and treatment response of schizophrenia has been investigated in a number of studies.35 The results of these studies have been inconsistent, but discussions about the impact of neuroactive steroids in the pathophysiology of schizophrenia are intriguing.

The sulfated form of DHEA is the most abundant neuroactive steroid in the blood.6,7 DHEA and DHEA-S regulate neuronal activity by means of slow mechanisms, such as gene expression, and by means of more rapid mechanisms, such as membrane-bound ligand-gated ion-channel interactions.1,8 DHEA and DHEA-S have been considered to have antistress and neuroprotective properties.2 Some studies have reported that the blood levels of these neuroactive steroids were lower in patients with schizophrenia than in healthy controls, but other studies have found elevated levels in patients with schizophrenia.4,5,9 These contradictory results make it difficult to form a hypothesis about the aforementioned relationships.

There are also inconsistent findings about the relationships between pathophysiology, prognosis, and symptom severity of schizophrenia and blood levels of progesterone, testosterone, and cortisol.1012 Most of the studies in this subfield investigated these relationships by measuring blood levels of patients with schizophrenia, regardless of their treatment status, the number of past episodes, and other confounding factors.3,1316 Moreover, patients with schizophrenia were frequently compared with healthy subjects. These studies did not measure alterations of blood levels of neuroactive steroids in different phases of the illness or compare blood levels of first-episode and later-episode patients. In the present study, we assessed potential differences in blood levels of DHEA-S, adrenocorticotropic hormone (ACTH), testosterone, progesterone, and cortisol between drug-naïve first-episode patients with schizophrenia (FES) and drug-free patients with schizophrenia who were not in the first episode but were in a phase of acute exacerbation (DFP).


Materials and methods
Participants

This study was conducted in the inpatient clinic at the Department of Psychiatry, Ankara Numune Research and Education Hospital. Sixty male patients who were diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR criteria17 were included in the study. Among them, 32 patients were experiencing their first episode of schizophrenia and had never been exposed to any antipsychotic drug (FES group). The other 28 patients had been diagnosed with schizophrenia at least 2 years prior, and were in an acute exacerbation stage of schizophrenia due to treatment nonadherence (DFP group). All of these 28 patients had been drug-free for at least 4 weeks for oral antipsychotics and at least 6 weeks for long-acting injectable antipsychotics. The diagnoses were made by senior psychiatrists. Twenty-four male and age-matched healthy control subjects (HC) were selected to provide blood samples.

The study was approved by the local ethics committee at the Ankara Numune Research and Education Hospital. All subjects provided written informed consent for participation in the study after the procedure had been fully explained. The exclusion criteria were 1) female sex, 2) the presence of any other psychiatric morbidity, such as alcohol or substance dependence, 3) the presence of any concurrent medical or endocrine disorder, and 4) the administration of other medications that could alter neurosteroid levels.

Procedure

All patients were clinically examined and individually interviewed. To obtain an objective history of the patients, accompanying close relatives were also interviewed. The patients were rated with the Scale for the Assessment of Negative Symptoms (SANS)18 and the Scale for the Assessment of Positive Symptoms (SAPS).19 Before initiating any pharmacological treatment, 10 mL of venous blood was collected at 8 am and divided into one tube with 2% heparin and another tube with ethylenediaminetetraacetic acid; this procedure was necessary to measure ACTH. Plasma levels of ACTH (normal range 7.2–63.3 pg/mL), cortisol (normal range 6.7–22.6 μg/dL), testosterone (normal range 8.9–42.5 pg/mL), progesterone (normal range 0.14–2.06 ng/mL), and DHEA-S (normal range 85–690 μg/dL) were measured by radioimmunoassay. Plasma levels of ACTH, cortisol, testosterone, progesterone, and DHEA-S were also collected from the consenting healthy subjects and measured using the same assay. To avoid interassay variability, the hormone levels in all groups were measured simultaneously.

Psychopathological assessment instruments
Structured Clinical Interview for DSM-IV Axis I

The Structured Clinical Interview for DSM-IV Axis I is a semistuctured interview for making major DSM-IV Axis I diagnoses. The instrument is designed to be administered by a clinician or trained mental health professional. It was developed by First et al,20 and the Turkish version was reported to be reliable by Corapcioglu et al.21

Scale for the Assessment of Negative Symptoms

The SANS assesses five symptom complexes to obtain clinical ratings of negative symptoms in patients with schizophrenia. These are affective blunting, alogia (impoverished thinking), avolition/apathy, anhedonia/asociality, and disturbance of attention. The final symptom complex seems to have less obvious relevance to negative symptoms than the other four complexes. Assessments are conducted on a 6-point scale (0= not at all to 5= severe). The instrument was developed by Andreasen.18 The Turkish version was reported to be reliable by Erkoç et al.22

Scale for the Assessment of Positive Symptoms

The SAPS was designed to assess positive symptoms, principally those that occur in schizophrenia. The instrument is intended to complement the SANS. The assessed positive symptoms include hallucinations, delusions, bizarre behavior, and positive formal thought disorder. The SAPS was developed by Andreasen.19 The Turkish version was reported to be reliable by Erkoç et al.23

Statistical methods

The data were analyzed using the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). When possible, results were presented with 95% confidence intervals (CIs), and two-tailed P-values of less than 0.05 were considered to be statistically significant for all analyses. The variables were tested for homogeneity of variance using Levene’s test, and for normality of distribution with the Kolmogorov–Smirnov test. Differences among age, serum levels of ACTH, cortisol, testosterone, progesterone, and DHEA-S were tested with a series of one-way analyses of variance. A Bonferroni test was applied in a post hoc analysis for multiple comparisons of the three groups. Student’s t-test was used for comparing SANS and SAPS scores between the FES and DFP patients. Differences in smoking status were compared with χ2 tests. Pearson correlation was performed to analyze the correlation coefficients among age, SANS and SAPS scores, duration of treatment, serum levels of ACTH, cortisol, testosterone, progesterone, and DHEA-S. Linear regression analysis was used to identify associations between age and levels of serum neurosteroids.


Results
Sociodemographic and clinical characteristics of the participants

All participants were male. The mean ages of the FES, DFP, and HC patients were 25.24±5.65, 28.92±4.81, and 26.67±5.19 years, respectively. The mean age was younger in the FES group than in the DFP group (F=3.58, P=0.033). Smoking status was similar among groups. The mean score of the SANS was higher in the DFP group than in the other groups (t=−2.25, P=0.02). The difference in the mean scores of the SAPS between the FES and DFP groups was not statistically significant (t=−1.62, P=0.10) (Table 1).

Serum ACTH, cortisol, testosterone, progesterone, and DHEA-S levels in the FES, DFS, and HC groups

The mean values of serum ACTH, cortisol, progesterone, and testosterone levels in the FES, DFP, and HC groups were similar. The mean serum DHEA-S levels were significantly different among the groups (F=29.13, P<0.001). A post hoc Bonferroni test revealed that the value of serum DHEA-S was higher in the FES group (330.68±78.87 μg/dL) than in the DFP group (132.87±44.97 μg/dL, P<0.001) and the HC group (179.81±52.82 μg/dL, P<0.001). The mean values of serum DHEA-S were found to be similar between the DFP and HC groups (P=0.33) (Table 2). Because the mean age was significantly different among the groups, regression was used to assess the association between age and plasma neurosteroids. There was only a significant association between level of serum cortisol and age in the HC group (P=0.02; adjusted R2=0.240, 0.355, and 0.453 in the FES, DFP, and HC groups respectively).

Correlations between age and SAPS and SANS scores and levels of plasma neurosteroids in the FES group

There was a negative correlation between the serum cortisol level and mean age (r=−0.523, P<0.001). There was a significant positive correlation between the mean SANS score and the serum ACTH level (r=0.352, P<0.05), and a negative correlation between the mean SANS score and the serum DHEA-S level (r=−0.546, P<0.001). The mean SAPS score was negatively correlated with the mean values of serum testosterone (r=−0.353, P<0.001) and cortisol (r=−0.620, P<0.001) (Table 3).

Correlations between age and SAPS and SANS scores, duration of treatment, and levels of plasma neurosteroids in the DFP group

There was a negative correlation between the serum ACTH level and mean age (r=−0.426, P<0.05) and a positive correlation between serum testosterone and mean age (r=0.561, P<0.001). There was a significant positive correlation between the mean SANS score and serum ACTH and cortisol levels (ACTH: r=0.490, P<0.001; cortisol: r=0.428, P<0.05). The mean SAPS score was negatively correlated with the values of serum cortisol (r=−0.415, P<0.001) and DHEA-S (r=−0.465, P<0.001). The duration of treatment was negatively correlated with the mean values of DHEA-S (r=−0.390, P<0.05) and ACTH (r=−0.560, P<0.001), and positively correlated with the mean serum testosterone level (r=0.673, P<0.001) (Table 4).


Discussion

Schizophrenia is a chronic and debilitating disorder characterized by various symptoms. Elevated emotional distress, cognitive decline, and deterioration in social functioning are core symptoms in schizophrenia.24 Regardless of the intensity of symptoms at the onset, diverse periods with variation in symptoms and symptom severity may occur during the course of the illness. As with other chronic medical conditions, patients who have the same diagnosis seldom experience the same symptoms over similar time periods. A patient with schizophrenia may experience a residual or remission period; the same patient may have been under treatment or drug-free for months. Moreover, the patient may be in an acute exacerbation period that involves acute and severe symptoms. This exacerbation may occur in spite of an effective treatment or as a result of giving up a treatment. Therefore, the validity of data that are obtained by comparing patients in different phases of a disease is questionable.

In this study, the most salient finding was higher blood levels of DHEA-S in the FES group compared to the DFP and HC groups. Notably, patients in the DFP group were not in remission or a residual period, but were in a state of acute exacerbation. Previous studies on the blood levels of DHEA or DHEA-S in patients with schizophrenia or other psychotic spectrum disorders have shown inconsistent results. Serum levels of DHEA and DHEA-S have been reported to be lower,25,26 similar,3,27 and elevated1315 in patients with schizophrenia. Several studies found increased blood levels of DHEA-S in FES compared to healthy controls, but the authors argued that this could not be seen in chronic patients; to our knowledge, no study has compared the blood levels of neurosteroids in male FES with those in male DFP. Therefore, previous research provides little evidence for assertions that higher levels of DHEA-S reflect a neuroprotective response to psychosis that becomes blunted as the illness becomes more chronic. However, our results provide evidence for this conclusion.

The findings of this study are consistent with previous interpretations (see especially Strous et al)14,15 suggesting that FES exhibit a neurosteroid response to psychosis. Higher values of DHEA-S levels in the FES group compared to both the DFP and HC groups indicate that this neurosteroid response is peculiar to FES patients. Neuroactive steroids, especially DHEA and DHEA-S, have long been known to have neuroprotective effects.2831 If elevated levels of these substances in the blood serve as neuroendocrinological adaptive or protective mechanisms, they would provide a one-time service for patients with schizophrenia. If this is the case, then treatment decisions for patients with schizophrenia should differ for single-episode versus chronic patients. An intrinsic protective mechanism may not occur after the first episode. There is no evidence that the mechanism is related to drug use, as this study shows that the blood levels of DHEA-S were lower in the DFP group than in the FES group; levels of neuroactive steroids may be diminished in subsequent episodes of the illness. In the present study, the decision to measure DHEA-S without DHEA reflects the fact that DHEA-S is the most abundant neuroactive steroid in circulation and a metabolite of DHEA. DHEA is a short-life molecule, and is metabolized rapidly to DHEA-S.32 Therefore, the levels of DHEA-S reflect the levels of DHEA, and increased DHEA-S levels indicate that DHEA levels recently increased.

Distress is known to cause increases in blood levels of neurosteroids.3335 In other psychiatric conditions that are accompanied by serious distress, blood levels of DHEA and DHEA-S were found to be elevated.36,37 Therefore, the question is which neurosteroid response is specific to which psychotic episode. Stress nonspecifically increases the blood levels of cortisol. In our study, there were no significant differences in serum ACTH or cortisol levels among the groups. Several neuroendocrinological studies emphasize that an uncertain dysfunction of the hypothalamic–pituitary–adrenal axis plays a role in the pathophysiology of schizophrenia,38,39 but there is insufficient evidence of this role in patients with schizophrenia. Given the variation on the schizophrenia spectrum, the study discrepancies in terms of blood levels of ACTH and cortisol are far from being severe. However, in our study, no significant differences in blood cortisol and ACTH levels were found among the groups; the similarities among the three groups show that the neurosteroid response is not a nonspecific response to stress. Nevertheless, in this study, the FES and DFP groups were similar in terms of symptom severity. Therefore, the results of this study are consistent with early suggestions about a diminished neurosteroid response in the later periods of illness.

In the present study, there were no significant differences in blood levels of testosterone and progesterone among the groups. Because various results have been found in previous studies, this finding should not be overinterpreted. In some studies, sample groups were taking medication, and the blood levels of some hormones may have been affected by the antipsychotics. In other studies, only patients with negative symptoms were considered. Oades and Schepker13 investigated serum steroid hormones in young patients with schizophrenia, and found no differences in blood levels of testosterone and progesterone in young male patients with schizophrenia compared to healthy controls and patients with obsessive compulsive disorder. However, their patients were not drug-naïve or drug-free, and many antipsychotic drugs are known to interfere with these measurements. Likewise, in their study, Shirayama et al37 found that the progesterone levels of patients with schizophrenia were similar with those of healthy controls, but they found that the testosterone levels were lower in the group of patients with moderate negative symptoms. Similarly, Goyal et al26 found no difference in blood levels of testosterone between patients with schizophrenia and healthy controls. Most of these studies included patient groups that were under medical treatment. In our study, neither patient groups was receiving any drug treatment; this criterion was selected so that the groups would be as homogeneous as possible. For the same reason, female patients were excluded from this study, as blood levels of some hormones, including progesterone, are known to vary during the menstrual period. Blood samples must be taken from female patients on the same days of the menstrual cycle to achieve valid results. This requirement is difficult and demanding for clinicians. Moreover, males are known to demonstrate higher DHEA-S levels.40 Late-onset schizophrenia and a better prognosis among females are patterns in need of explanation, so there would have been many confounding factors if females had been included in the study.

Researching peripheral blood biomarkers for schizophrenia enhances the potential to discover diagnostic and prognostic indicators of utility and to understand the pathophysiology of schizophrenia.41 In addition to neuroendocrinological and neuroimaging studies that investigated potential biomarkers for schizophrenia, there are several studies that have explored immunological factors and the association between schizophrenia and antipsychotic therapy. Himmerich et al reported that there were significant impacts of antipsychotics on interleukin levels in vivo.42 Another study by Borovcanin et al, in which the grouping of participants was similar to our study, reported that type II cytokine levels were elevated, and there were low interleukin 17 levels in FES patients and patients with schizophrenia who were in relapse.43 In a review, Schmidt et al noted the roles of eicosanoids and related enzymes in the etiology and treatment of schizophrenia.44 In addition to highlighting the presence of neuroprotective and stress-response roles of elevated DHEA-S levels in FES patients, elevated DHEA-S may be considered to be a biomarker for schizophrenia. However, further studies are needed to identify the biomarker role of DHEA-S in schizophrenia.

There are several limitations of the present study. The major limitation is its design. Comparing neurosteroids in the same first-episode and later-episode schizophrenia patients may be the best way to achieve reliable results. However, comparing biomarkers in patients with schizophrenia in their first episode and in subsequent episodes may be impossible to achieve while the patients remain drug-free. We could not investigate blood levels of antipsychotics, so our antipsychotic treatment data were obtained from patients and their first-degree relatives. Because of our study design, only male patients were included in the study, which may be considered to be a limitation. Another limitation is that patients who were suffering from their first episode of schizophrenia were younger, which is to be expected. Finally, patients with obesity were not included in the study, and we have no data that would determine whether body mass index has an association with serum neurosteroid levels.

In conclusion, our study provides valid evidence in support of previous hypotheses in this field of research. Further prospective studies should investigate the differences in blood levels of neurosteroids in patients with schizophrenia.


Notes

Disclosure

The authors report no conflicts of interest in this work.

References
1. Paul SM,Purdy RH. Neuroactive SteroidsFASEB JYear: 19926231123221347506
2. Maninger N,Wolkowitz OM,Reus VI,Epel ES,Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)Front NeuroendocrinolYear: 200930659119063914
3. Ritsner M,Maayan R,Gibel A,Strous RD,Modai I,Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patientsEur NeuropsychopharmacolYear: 20041426727315163435
4. Lerer B,Ran A,Blacker M,et al. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunctionSchizophr ResYear: 198814054103154528
5. Meltzer HY,Lee MA,Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophreniaNeuropsychopharmacologyYear: 20012427829011166518
6. Baulieu EE,Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive steroidsJ EndocrinolYear: 1996150221239
7. Wolf OT,Neumann O,Hellhammer DH,et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and menJ Clin Endocrinol MetabYear: 199782236323679215320
8. Rupprecht R,di Michelle F,Hermann B,et al. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacologyBrain Res Brain Res RevYear: 200137596711744074
9. Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trialsCNS Neurosci TherYear: 201016324420070787
10. Alexander GM,Peterson BS. Sex steroids and human behavior: implications for developmental psychopathologyCNS SpectrYear: 20016758817008833
11. Walder DJ,Walker EF,Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophreniaBiol PsychiatryYear: 2000481121113211137052
12. Brophy MH,Rush JA,Crowley G. Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenicsBiol PsychiatryYear: 1983185835906222771
13. Oades RD,Schepker R. Serum gonadal steroid hormones in young schizophrenic patientsPsychoneuroimmunologyYear: 199419373385
14. Strous RD,Maayan R,Lapidus R,et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatologySchizophr ResYear: 20047142743415474914
15. Strous RD,Maayan R,Kaminsky M,Blumensohn R,Weizman A,Spivak B. DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: a comparison studyEur NeuropsychopharmacolYear: 20091949950319351578
16. Yıldırım O,Dogan O,Semiz M,Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relativesPsychiatry Clin NeurosciYear: 20116558459121895860
17. American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashingtonAmerican Psychiatric AssociationYear: 2000
18. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS)Iowa CityCollege of Medicine, University of IowaYear: 1984
19. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS)Iowa CityCollege of Medicine, University of IowaYear: 1984
20. First MB,Spitzer RL,Gibbon M,Williams JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician VersionWashingtonAmerican Psychiatric PressYear: 1996
21. Corapcioglu A,Aydemir O,Yildiz M. Structured clinical interview for DSM-IV (SCID-IV): Turkish version]AnkaraHekimler Yayin BirligiYear: 1999 Turkish.
22. Erkoç S,Arkonaç O,Ataklı C,Ozmen E. Negatif semptomları değerlendirme ölçeğinin güvenirliği ve geçerliliği. [The reliability and validity of scale for the assessment of negative symptoms.]Düşünen AdamYear: 199141619
23. Erkoç S,Arkonaç O,Ataklı C,Ozmen E. Pozitif semptomları değerlendirme ölçeğinin güvenirlirliği ve geçerliliği. [The reliability and validity of scale for the assessment of positive symptoms.]Düşünen AdamYear: 199142024
24. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment optionsCan J PsychiatryYear: 1997422552649114941
25. Tourney G,Erb JL. Temporal variations in androgens and stress hormones in control and schizophrenic subjectsBiol PsychiatryYear: 197914395404157785
26. Goyal RO,Sagar R,Ammini AC,Khurana ML,Alias AG. Negative correlation between negative symptoms of schizophrenia and testosterone levelsAnn N Y Acad SciYear: 2004103229129415677432
27. Yilmaz N,Herken H,Cicek HK,Celik A,Yurekli M,Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophreniaMed Princ PractYear: 20071613714117303950
28. Maayan R,Yagorowski Y,Grupper D,et al. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatientsBiol PsychiatryYear: 20004869370111032981
29. Kaasik A,Safiulina D,Kalda A,Zharkovsky A. Dehydroepiandrosterone sulphate prevents oxygen-glucose deprivation-induced injury in cerebellar granule cell cultureNeuroscienceYear: 200110242743211166128
30. Kimonides VG,Khatibi NH,Svendsen CN,Sofroniew MV,Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S) protect hippocampal neurons against excitatory amino acid-induced neurotoxicityProc Natl Acad Sci U S AYear: 199895185218579465106
31. Zhang L,Li B,Ma W,et al. Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEAS) regulate apoptosis during neurogenesis by triggering the Akt signalling pathway in opposing waysBrain Res Mol Brain ResYear: 200298586611834296
32. Rosenfeld RS,Rosenberg BJ,Fukushima DK,Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfateClin Endocrinol MetabYear: 197540850855
33. Corpéchot C,Robel P,Axelson M,Sjövall J,Baulieu EE. Characterization and measurement of dehydroepiandrosterone sulfate in rat brainProc Natl Acad Sci U S AYear: 198178470447076458035
34. Oberbeck R,Benschop RJ,Jacobs R,et al. Endocrine mechanisms of stress-induced DHEA secretionJ Endocrinol InvestYear: 1998211481539591209
35. Söndergaard HP,Hansson LO,Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in SwedenPsychother PsychosomYear: 20027129830312207110
36. Spivak B,Maayan R,Kotler M,et al. Elevated circulatory levels of GABA(A)-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorderPsychol MedYear: 2000301227123112027057
37. Shirayama Y,Hashimoto K,Suzuki Y,Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophreniaSchizophr ResYear: 200258697412363392
38. Marx CE,Lieberman JA. Psychoneuroendocrinology of schizophreniaPsychiatr Clin North AmYear: 1988214134349670234
39. Walker EF,Diforio D. Schizophrenia: a neural diathesis-stress modelPsychol RevYear: 19971046676859337628
40. Orentreich N,Brind JL,Vogelman JH,Andres R,Baldwin H. Long term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal menJ Clin Endocrinol MetabYear: 199275100210041400863
41. Chana G,Bousman CA,Money TT,et al. Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosisFront Cell NeurosciYear: 201379523805071
42. Himmerich H,Schönherr J,Fulda S,Sheldrick AJ,Bauer K,Sack U. Impact of antipsychotics on cytokine production in-vitroJ Psychiatr ResYear: 2011451358136521592521
43. Borovcanin M,Jovanovic I,Radosavljevic G,et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapseJ Psychiatr ResYear: 2012461421142622974591
44. Schmidt L,Ceglarek U,Kortz L,et al. Mechanisms of involvement of eicosanoids and their precursors in the pathophysiology and treatment of schizophreniaMed ChemYear: 2013976377323590232

Article Categories:
  • Original Research

Keywords: Keywords neurosteroid, effect, psychosis.

Previous Document:  Solitary skull metastasis as the first symptom of hepatocellular carcinoma: case report and literatu...
Next Document:  Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid a...